

# Brendan T Griffin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/207293/publications.pdf>

Version: 2024-02-01

90  
papers

3,499  
citations

126907

33  
h-index

149698

56  
g-index

91  
all docs

91  
docs citations

91  
times ranked

4809  
citing authors

#	ARTICLE	IF	CITATIONS
1	Biopharmaceutical challenges associated with drugs with low aqueous solubilityâ€”The potential impact of lipid-based formulations. <i>Advanced Drug Delivery Reviews</i> , 2008, 60, 617-624.	13.7	252
2	Gut Reactions: Breaking Down Xenobioticâ€™s Microbiome Interactions. <i>Pharmacological Reviews</i> , 2019, 71, 198-224.	16.0	211
3	Lipid-based nanocarriers for oral peptide delivery. <i>Advanced Drug Delivery Reviews</i> , 2016, 106, 337-354.	13.7	204
4	Interactions between antidepressants and P-glycoprotein at the bloodâ€™s brain barrier: clinical significance of <i>in vitro</i> and <i>in vivo</i> findings. <i>British Journal of Pharmacology</i> , 2012, 165, 289-312.	5.4	171
5	Impact of gastrointestinal tract variability on oral drug absorption and pharmacokinetics: An UNGAP review. <i>European Journal of Pharmaceutical Sciences</i> , 2021, 162, 105812.	4.0	137
6	From Belly to Brain: Targeting the Ghrelin Receptor in Appetite and Food Intake Regulation. <i>International Journal of Molecular Sciences</i> , 2017, 18, 273.	4.1	112
7	Comparison of <i>in vitro</i> tests at various levels of complexity for the prediction of <i>in vivo</i> performance of lipid-based formulations: Case studies with fenofibrate. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2014, 86, 427-437.	4.3	111
8	Drugâ€™s gut microbiota interactions: implications for neuropharmacology. <i>British Journal of Pharmacology</i> , 2018, 175, 4415-4429.	5.4	93
9	Current challenges and future perspectives in oral absorption research: An opinion of the UNGAP network. <i>Advanced Drug Delivery Reviews</i> , 2021, 171, 289-331.	13.7	84
10	Pharmacokinetic, pharmacodynamic and biodistribution following oral administration of nanocarriers containing peptide and protein drugs. <i>Advanced Drug Delivery Reviews</i> , 2016, 106, 367-380.	13.7	83
11	Impact of body composition parameters on clinical outcomes in patients with metastatic castrate-resistant prostate cancer treated with docetaxel. <i>Clinical Nutrition ESPEN</i> , 2016, 13, e39-e45.	1.2	81
12	The Impact of the Gut Microbiota on Drug Metabolism and Clinical Outcome. <i>Yale Journal of Biology and Medicine</i> , 2016, 89, 375-382.	0.2	78
13	Lipophilicity and hydrophobicity considerations in bio-enabling oral formulations approaches â€™ a PEARRL review. <i>Journal of Pharmacy and Pharmacology</i> , 2019, 71, 464-482.	2.4	76
14	Food for thought: formulating away the food effect â€™ a PEARRL review. <i>Journal of Pharmacy and Pharmacology</i> , 2019, 71, 510-535.	2.4	75
15	Microbiome-mediated bile acid modification: Role in intestinal drug absorption and metabolism. <i>Pharmacological Research</i> , 2018, 133, 170-186.	7.1	66
16	Pharmacotherapy for Neonatal Seizures: Current Knowledge and Future Perspectives. <i>Drugs</i> , 2016, 76, 647-661.	10.9	64
17	A comparison of intestinal lymphatic transport and systemic bioavailability of saquinavir from three lipid-based formulations in the anaesthetised rat model. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 58, 917-925.	2.4	57
18	<i>Lactococcus lactis</i> as a Cell Factory for Delivery of Therapeutic Proteins. <i>Current Gene Therapy</i> , 2010, 10, 34-45.	2.0	56

#	ARTICLE	IF	CITATIONS
19	A novel lipid-based solid dispersion for enhancing oral bioavailability of Lycopene – In vivo evaluation using a pig model. <i>International Journal of Pharmaceutics</i> , 2013, 453, 307-314.	5.2	54
20	Impact of Gut Microbiota-Mediated Bile Acid Metabolism on the Solubilization Capacity of Bile Salt Micelles and Drug Solubility. <i>Molecular Pharmaceutics</i> , 2017, 14, 1251-1263.	4.6	54
21	Regulation of biosimilar medicines and current perspectives on interchangeability and policy. <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 1-11.	1.9	54
22	The pig as a preclinical model for predicting oral bioavailability and in vivo performance of pharmaceutical oral dosage forms: a PEARRL review. <i>Journal of Pharmacy and Pharmacology</i> , 2019, 71, 581-602.	2.4	53
23	Folate-targeted amphiphilic cyclodextrin.siRNA nanoparticles for prostate cancer therapy exhibit PSMA mediated uptake, therapeutic gene silencing in vitro and prolonged circulation in vivo. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2016, 12, 2341-2351.	3.3	48
24	Lactococcus lactis-expressing listeriolysin O (LLO) provides protection and specific CD8+ T cells against Listeria monocytogenes in the murine infection model. <i>Vaccine</i> , 2008, 26, 5304-5314.	3.8	47
25	P-glycoprotein Inhibition Increases the Brain Distribution and Antidepressant-Like Activity of Escitalopram in Rodents. <i>Neuropsychopharmacology</i> , 2013, 38, 2209-2219.	5.4	47
26	PEGylated cyclodextrins as novel siRNA nanosystems: Correlations between polyethylene glycol length and nanoparticle stability. <i>International Journal of Pharmaceutics</i> , 2014, 473, 105-112.	5.2	45
27	Assessing awareness and attitudes of healthcare professionals on the use of biosimilar medicines: A survey of physicians and pharmacists in Ireland. <i>Regulatory Toxicology and Pharmacology</i> , 2017, 88, 252-261.	2.7	45
28	Bioavailability of lycopene in the rat: the role of intestinal lymphatic transport. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 62, 323-331.	2.4	41
29	Inhibition of P-glycoprotein enhances transport of imipramine across the blood-brain barrier: microdialysis studies in conscious freely moving rats. <i>British Journal of Pharmacology</i> , 2012, 166, 1333-1343.	5.4	41
30	Silicon microfluidic flow focusing devices for the production of size-controlled PLGA based drug loaded microparticles. <i>International Journal of Pharmaceutics</i> , 2014, 467, 60-69.	5.2	39
31	Application of the solubility parameter concept to assist with oral delivery of poorly water-soluble drugs – a PEARRL review. <i>Journal of Pharmacy and Pharmacology</i> , 2019, 71, 441-463.	2.4	39
32	The gut microbiome influences the bioavailability of olanzapine in rats. <i>EBioMedicine</i> , 2021, 66, 103307.	6.1	38
33	Human P-glycoprotein differentially affects antidepressant drug transport: relevance to blood-brain barrier permeability. <i>International Journal of Neuropsychopharmacology</i> , 2013, 16, 2259-2272.	2.1	37
34	Biopharmaceutical Modeling of Drug Supersaturation During Lipid-Based Formulation Digestion Considering an Absorption Sink. <i>Pharmaceutical Research</i> , 2014, 31, 3426-3444.	3.5	35
35	Characterization of gastrointestinal transit and luminal conditions in pigs using a telemetric motility capsule. <i>European Journal of Pharmaceutical Sciences</i> , 2021, 156, 105627.	4.0	31
36	Best practices in current models mimicking drug permeability in the gastrointestinal tract - An UNGAP review. <i>European Journal of Pharmaceutical Sciences</i> , 2022, 170, 106098.	4.0	29

#	ARTICLE	IF	CITATIONS
37	Lipidic dispersion to reduce food dependent oral bioavailability of fenofibrate: In vitro, in vivo and in silico assessments. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2015, 96, 207-216.	4.3	28
38	Exploring the Impact of Drug Properties on the Extent of Intestinal Lymphatic Transport - In Vitro and In Vivo Studies. <i>Pharmaceutical Research</i> , 2015, 32, 1817-1829.	3.5	28
39	Nisin inducible production of listeriolysin O in <i>Lactococcus lactis</i> NZ9000. <i>Microbial Cell Factories</i> , 2008, 7, 24.	4.0	27
40	Efficacy of a <i>Lactococcus lactis</i> <i>pyrG</i> vaccine delivery platform expressing chromosomally integrated <i>hly</i> from <i>Listeria monocytogenes</i> . <i>Bioengineered Bugs</i> , 2010, 1, 66-74.	1.7	27
41	Opportunities and challenges for oral delivery of hydrophobic versus hydrophilic peptide and protein-like drugs using lipid-based technologies. <i>Therapeutic Delivery</i> , 2011, 2, 1633-1653.	2.2	27
42	In vitro dissolution models for the prediction of in vivo performance of an oral mesoporous silica formulation. <i>Journal of Controlled Release</i> , 2017, 250, 86-95.	9.9	27
43	Knowledge of Adverse Drug Reaction Reporting and the Pharmacovigilance of Biological Medicines: A Survey of Healthcare Professionals in Ireland. <i>BioDrugs</i> , 2018, 32, 267-280.	4.6	26
44	The effect of organic anion transporter 3 inhibitor probenecid on bumetanide levels in the brain: an integrated <i>in vivo</i> microdialysis study in the rat. <i>Journal of Pharmacy and Pharmacology</i> , 2015, 67, 501-510.	2.4	26
45	Enhanced colonic delivery of ciclosporin A self-emulsifying drug delivery system encapsulated in coated minispheres. <i>Drug Development and Industrial Pharmacy</i> , 2016, 42, 245-253.	2.0	25
46	Impact of host and environmental factors on $\beta$ -glucuronidase enzymatic activity: implications for gastrointestinal serotonin. <i>American Journal of Physiology - Renal Physiology</i> , 2020, 318, G816-G826.	3.4	25
47	Exploring the Impact of Surfactant Type and Digestion: Highly Digestible Surfactants Improve Oral Bioavailability of Nilotinib. <i>Molecular Pharmaceutics</i> , 2020, 17, 3202-3213.	4.6	24
48	Expression of two <i>Listeria monocytogenes</i> antigens (P60 and LLO) in <i>Lactococcus lactis</i> and examination for use as live vaccine vectors. <i>Journal of Medical Microbiology</i> , 2010, 59, 904-912.	1.8	23
49	New Insights into Using Lipid Based Suspensions for "Brick Dust"™ Molecules: Case Study of Nilotinib. <i>Pharmaceutical Research</i> , 2019, 36, 56.	3.5	23
50	A Retrospective Biopharmaceutical Analysis of >800 Approved Oral Drug Products: Are Drug Properties of Solid Dispersions and Lipid-Based Formulations Distinctive?. <i>Journal of Pharmaceutical Sciences</i> , 2020, 109, 3248-3261.	3.3	19
51	Supersaturated Lipid-Based Formulations to Enhance the Oral Bioavailability of Venetoclax. <i>Pharmaceutics</i> , 2020, 12, 564.	4.5	19
52	Novel Biphasic Lipolysis Method To Predict <i>in Vivo</i> Performance of Lipid-Based Formulations. <i>Molecular Pharmaceutics</i> , 2020, 17, 3342-3352.	4.6	18
53	In vitro bidirectional permeability studies identify pharmacokinetic limitations of NKCC1 inhibitor bumetanide. <i>European Journal of Pharmacology</i> , 2016, 770, 117-125.	3.5	17
54	Exploring impact of supersaturated lipid-based drug delivery systems of celecoxib on in vitro permeation across Permeapad™ membrane and in vivo absorption. <i>European Journal of Pharmaceutical Sciences</i> , 2020, 152, 105452.	4.0	17

#	ARTICLE	IF	CITATIONS
55	Machine learning methods for prediction of food effects on bioavailability: A comparison of support vector machines and artificial neural networks. <i>European Journal of Pharmaceutical Sciences</i> , 2022, 168, 106018.	4.0	17
56	Exploring precipitation inhibitors to improve in vivo absorption of cinnarizine from supersaturated lipid-based drug delivery systems. <i>European Journal of Pharmaceutical Sciences</i> , 2021, 159, 105691.	4.0	16
57	Models of the Small Intestine. , 2008, , 34-76.		14
58	Mesoporous silica-based dosage forms improve bioavailability of poorly soluble drugs in pigs: case example fenofibrate. <i>Journal of Pharmacy and Pharmacology</i> , 2017, 69, 1284-1292.	2.4	14
59	Exploring gastric emptying rate in minipigs: Effect of food type and pre-dosing of metoclopramide. <i>European Journal of Pharmaceutical Sciences</i> , 2018, 118, 183-190.	4.0	14
60	Sustained-release multiparticulates for oral delivery of a novel peptidic ghrelin agonist: Formulation design and in vitro characterization. <i>International Journal of Pharmaceutics</i> , 2018, 536, 63-72.	5.2	14
61	Development and evaluation of a biorelevant medium simulating porcine gastrointestinal fluids. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2020, 154, 116-126.	4.3	14
62	Supersaturated lipid-based drug delivery systems – exploring impact of lipid composition type and drug properties on supersaturability and physical stability. <i>Drug Development and Industrial Pharmacy</i> , 2020, 46, 356-364.	2.0	14
63	Gut microbiome-mediated modulation of hepatic cytochrome P450 and P-glycoprotein: impact of butyrate and fructo-oligosaccharide-inulin. <i>Journal of Pharmacy and Pharmacology</i> , 2020, 72, 1072-1081.	2.4	13
64	An Examination of the Effect of Intestinal First Pass Extraction on Intestinal Lymphatic Transport of Saquinavir in the Rat. <i>Pharmaceutical Research</i> , 2008, 25, 1125-1133.	3.5	12
65	Rational Selection of Bio-Enabling Oral Drug Formulations – A PEARRL Commentary. <i>Journal of Pharmaceutical Sciences</i> , 2021, 110, 1921-1930.	3.3	12
66	The P-glycoprotein inhibitor cyclosporin A differentially influences behavioural and neurochemical responses to the antidepressant escitalopram. <i>Behavioural Brain Research</i> , 2014, 261, 17-25.	2.2	11
67	<i>In Silico</i> , <i>In Vitro</i> , and <i>In Vivo</i> Evaluation of Precipitation Inhibitors in Supersaturated Lipid-Based Formulations of Venetoclax. <i>Molecular Pharmaceutics</i> , 2021, 18, 2174-2188.	4.6	11
68	Application of a physiologically-based pharmacokinetic model for the prediction of bumetanide plasma and brain concentrations in the neonate. <i>Biopharmaceutics and Drug Disposition</i> , 2018, 39, 125-134.	1.9	9
69	Chase Dosing of Lipid Formulations to Enhance Oral Bioavailability of Nilotinib in Rats. <i>Pharmaceutical Research</i> , 2020, 37, 124.	3.5	8
70	Oral biopharmaceutics tools: recent progress from partnership through the Pharmaceutical Education and Research with Regulatory Links collaboration. <i>Journal of Pharmacy and Pharmacology</i> , 2021, 73, 437-446.	2.4	8
71	Combining species specific in vitro & in silico models to predict in vivo food effect in a preclinical stage – case study of Venetoclax. <i>European Journal of Pharmaceutical Sciences</i> , 2021, 162, 105840.	4.0	8
72	Artificial Neural Networks to Predict the Apparent Degree of Supersaturation in Supersaturated Lipid-Based Formulations: A Pilot Study. <i>Pharmaceutics</i> , 2021, 13, 1398.	4.5	8

#	ARTICLE	IF	CITATIONS
73	Treating disorders of the neonatal central nervous system: pharmacokinetic and pharmacodynamic considerations with a focus on antiepileptics. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 62-77.	2.4	7
74	Developing Clinically Relevant Dissolution Specifications (CRDSs) for Oral Drug Products: Virtual Webinar Series. <i>Pharmaceutics</i> , 2022, 14, 1010.	4.5	7
75	Broadband Acoustic Resonance Dissolution Spectroscopy (BARDS): A rapid test for enteric coating thickness and integrity of controlled release pellet formulations. <i>International Journal of Pharmaceutics</i> , 2018, 544, 31-38.	5.2	6
76	Toward simplified oral lipid-based drug delivery using mono-/di-glycerides as single component excipients. <i>Drug Development and Industrial Pharmacy</i> , 2020, 46, 2051-2060.	2.0	6
77	Behavioural characterization of ghrelin ligands, anamorelin and HM01: Appetite and reward-motivated effects in rodents. <i>Neuropharmacology</i> , 2020, 168, 108011.	4.1	6
78	Chronic P-glycoprotein inhibition increases the brain concentration of escitalopram: potential implications for treating depression. <i>Pharmacology Research and Perspectives</i> , 2015, 3, e00190.	2.4	5
79	A Dairy-Derived Ghrelinergic Hydrolysate Modulates Food Intake In Vivo. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2780.	4.1	5
80	Applying Computational Predictions of Biorelevant Solubility Ratio Upon Self-Emulsifying Lipid-Based Formulations Dispersion to Predict Dose Number. <i>Journal of Pharmaceutical Sciences</i> , 2021, 110, 164-175.	3.3	5
81	Synthesis and In Vivo Evaluation of Insulin-Loaded Whey Beads as an Oral Peptide Delivery System. <i>Pharmaceutics</i> , 2021, 13, 656.	4.5	4
82	Gut microbiota-drug interactions in cancer pharmacotherapies: implications for efficacy and adverse effects. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2022, 18, 5-26.	3.3	4
83	Toward the establishment of a standardized pre-clinical porcine model to predict food effects – Case studies on fenofibrate and paracetamol. <i>International Journal of Pharmaceutics: X</i> , 2019, 1, 100017.	1.6	3
84	The PEARRL reviews – innovative drug development strategies tailored to facilitate earlier access to new oral medicines. <i>Journal of Pharmacy and Pharmacology</i> , 2019, 71, 439-440.	2.4	3
85	Lipophilic salts and lipid-based formulations for bridging the food effect gap of venetoclax. <i>Journal of Pharmaceutical Sciences</i> , 2021, , .	3.3	3
86	Exploring porcine gastric and intestinal fluids using microscopic and solubility estimates: Impact of placebo self-emulsifying drug delivery system administration to inform bio-predictive in vitro tools. <i>European Journal of Pharmaceutical Sciences</i> , 2021, 161, 105778.	4.0	2
87	Perspectives of pharmacists on facilitating experiential learning placements for pharmacy students in non-patient facing settings. <i>Currents in Pharmacy Teaching and Learning</i> , 2020, 12, 901-909.	1.0	2
88	A phase 1, single-blind, placebo-controlled, 3-arm cross-over trial assessing the appetite enhancing effects of potentially ghrelinergic dairy-derived peptides. <i>Proceedings of the Nutrition Society</i> , 2020, 79, .	1.0	0
89	Impact of body composition parameters on clinical outcomes in patients with metastatic castration-resistant prostate cancer treated with docetaxel. <i>Journal of Clinical Oncology</i> , 2015, 33, e16121-e16121.	1.6	0
90	Regulatory Science Ireland: bridging the information gap on biosimilar medicines. <i>GaBI Journal</i> , 2016, 5, 168-170.	0.3	0